– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion.
–In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion–
iOmx Therapeutics to present new data on lead programs and I/O target screening platform at AACR 2024 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the phase 1 clinical trial of OT-A201 (Study No. A20101), a first-in-class bispecific antibody targeting two immune checkpoints is in progress.
- Interim results from Phase 2 innovaTV 207 trial of tisotumab vedotin in head and neck cancer to be presented Initial Phase 1 dose-escalation data for SEA-TGT monotherapy in advanced malignancies to be disclosed Preclinical data and discovery research underscore Seagen’s mission to innovate through next-gener.